RecruitMe Clinical Trial

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
Study of MK-8228 (Letermovir) vs. Valganciclovir for Prevention of CMV Disease in Adult Kidney Transplant Recipients
Sponsor:Merck Sharpe & Dohme Corp.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR7454
U.S. Government ID:NCT03443869
Contact: Cristina Falo, PhD: 212-305-3839 / cf2427@cumc.columbia.edu
Additional Study Information:

The MK-8228-002 Study is studying the safety and effectiveness of an investigational medication for preventing cytomegalovirus (CMV) disease in adults with kidney transplants. The MK-8228-002 Study is evaluating an investigational medication (known as MK-8228) versus valganciclovir (VGCV). VGCV is an antiviral medication and is the current standard of care for CMV disease prevention in kidney transplant recipients. The study will last for approximately one year (52 weeks). Study treatment will start within seven days post-transplant and continue through 28 weeks. In total, subjects will be monitored for CMV disease for approximately a year after transplant.

Do You Qualify?
Have you been told you tested positive for cytomegalovirus (CMV)?YesNo
Will you receive a kidney transplant soon?YesNo
Are you a multi-organ transplant recipient?YesNo
Are you on dialysis?YesNo
Are you pregnant or are you expecting to donate eggs or sperm?YesNo
Submit
Cancel
Investigator
Marcus Pereira, MD, MPH
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Cristina Falo, PhD
Email: cf2427@cumc.columbia.edu
Phone: 212-305-3839